$VYGR

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Robin Swartz On October 20, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Voyager The

Voyager Therapeutics (VYGR) appointed Robin Swartz as President, effective Oct. 20, 2026, and expects her to succeed Alfred W. Sandrock as CEO in Q1 2027. The transition is pending the enrollment and initial safety data for VY1706. Sandrock is expected to join the Board after the transition.

Morgan Stanley reduced its price target for Voyager Technologies from $37 to $36. The stock closed at $26.76, up 3.64% over 5 days but down 5.04% year-to-date. The adjustment is based on valuation, EPS revisions, and visibility metrics.

Viking Therapeutics raised ~$547.8M in net proceeds from a $575M offering of common stock and convertible notes. The offering included 9,035,714 shares at $35.00 each and $258.75M in notes due 2032. Underwriters exercised options for additional shares and notes.

Viking Therapeutics priced a $500 million upsized offering of common shares and convertible senior notes due in 2032. The company's stock is currently trading at $41.65, up 1.96% in pre-market. This follows a previous announcement of plans for the offering.

Voyager Technologies' shares dropped 7.8% in after-hours trading after announcing a $350 million convertible senior notes offering. The company plans to use proceeds for capped call transactions, general corporate purposes, and expansion. Shares closed at $37.53, up 44% year-to-date.

Viking Therapeutics' stock rose 40% premarket after trial data showed its obesity drug VK2735 maintained weight loss with less frequent dosing. Patients kept 97% of weight loss on biweekly dosing and 90% on monthly dosing. Analysts highlight potential clinical advantages. The company aims to compete with Novo Nordisk and Eli Lilly in a market projected to reach $100B by 2030.

Voyager Therapeutics (NASDAQ:VYGR) reported second-quarter results. Shares rose 7.9% to $3.27. Revenues were 31% below analyst predictions, while losses of $0.40 per share were 20% smaller than expected. Analysts now forecast 2026 revenue of $46.0m (up from $39.3m) and losses of $1.87 per share, with the consensus price target unchanged at $14.89.

Voyager Therapeutics, Inc. (VYGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Voyager Reports Second Quarter 2026 Financial and Operating Results - VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., August 6, 2026 -- Voyager Therape

Ahead of Q2 earnings, Morgan Stanley kept a constructive view on aerospace and defense, citing resilient commercial demand, improving aircraft production, and durable aftermarket needs. It noted Boeing 737 MAX at 47 aircraft per month. For defense, it argued a $1.1T FY2027 base budget is underestimated. It downgraded Loar and TransDigm, cut CAE and Voyager, and adjusted price targets for multiple firms.